Eli Lilly stock dips on Novo Nordisk's rival drug data
Shares of pharmaceutical giant Eli Lilly (NYSE:LLY) edged down 1.2% in premarket trading following announcements from ...
Novo Rises as Experimental Shot Shows 22% Weight Loss
Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.
Investor's Business Daily on MSN38m
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
Novo Nordisk reported strong early-stage results for its once-a-week obesity drug. Early Friday, Novo Nordisk stock jumped. Eli Lilly fell.